3.770USD+0.40%Mkt Cap: 606.58M USDP/E: —Last update: 2026-06-01
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabt…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap606.58M USD
Enterprise Value526.16M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-167.86M USD
Revenue/Share—
Last Price3.770 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees156
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.57
PEG—
EV/EBITDA-2.96
EV/Revenue—
P/S—
P/B4.07
EPS (TTM)-1.78
EPS (Forward)-1.47
52W Range
1.26085% of range4.230
52W High4.230 USD
52W Low1.260 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-149.80%
ROA-101.68%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-131.08M USD
CapEx (TTM)1.23M USD
FCF Margin—
FCF Yield-14.97%
Net Debt-90.19M USD
Net Debt/EBITDA0.51
Balance Sheet
Debt/Equity0.24
Current Ratio2.95
Quick Ratio2.81
Book Value/Sh0.9280 USD
Cash/Share0.7150 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Target (Mean)13.38 USD
Target Range4.000 USD – 30.00 USD
# Analysts8
Ownership
Shares Out.163.05M
Float142.90M
Insiders0.99%
Institutions54.26%
Short Interest
Short Ratio5.0d
Short % Float15.51%
Short % Out.14.01%
Shares Short22.84M
Short (prev mo.)19.64M
Technical
SMA 503.242 (+16.3%)
SMA 2002.631 (+43.3%)
Beta3.17
S&P 52W Chg27.94%
Avg Vol (30d)4.11M
Avg Vol (10d)3.15M
Technical Indicators
RSI (14)57.1
MACD0.1292
MACD Signal0.1172
MACD Hist.+0.0120
BB Upper4.216 USD
BB Middle3.648 USD
BB Lower3.080 USD
BB Width31.12%
ATR (14)0.2729 USD
Vol Ratio (20d)0.30x